About: Dynamic profiles, biodistribution and integration evaluation after intramuscular/intravenous delivery of a novel therapeutic DNA vaccine encoding chicken type II collagen for rheumatoid arthritis in vaccinated normal rodent

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Dynamic profiles, biodistribution and integration evaluation after intramuscular/intravenous delivery of a novel therapeutic DNA vaccine encoding chicken type II collagen for rheumatoid arthritis in vaccinated normal rodent Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Dynamic profiles, biodistribution and integration evaluation after intramuscular/intravenous delivery of a novel therapeutic DNA vaccine encoding chicken type II collagen for rheumatoid arthritis in vaccinated normal rodent
Creator	Liu, Nan Zhao, Xiao Liang, Fei Long, Juan Sun, Yuying Xi, Yongzhi
source	Medline; PMC
abstract	BACKGROUND: The persistence, biodistribution, and risk of integration into the host genome of any new therapeutic DNA vaccine must be established in preclinical studies. We previously developed the DNA vaccine pcDNA-CCOL2A1 encoding chicken type II collagen (CCII) for the treatment of rheumatoid arthritis (RA). In the present study, we characterized its dynamic profile, biodistribution, and potential for genomic DNA integration in normal vaccinated rodent. RESULTS: A real-time quantitative PCR analysis (RT-qPCR) of animals administered a single dose of pcDNA-CCOL2A1 (300 μg/kg by intramuscular injection) showed that CCOL2A1 mRNA level in the blood peaked between 2 and 6 h post-immunization and then rapidly declined, and was undetectable between day 1–42. CCOL2A1 transcript was detected at the muscle injection site on days 3–14 post-immunization. Starting from day 14, the transcript was detected in the heart, liver, lung, and kidney but not in the spleen or thymus, and was expressed only in the lung on day 28. There was no CCOL2A1 mRNA present in the testes or ovaries at any time point. Non-invasive in vivo fluorescence imaging revealed CCII protein expression from 2 h up to day 10 and from 2 h up to day 35 after administration of pcDNA-CCOL2A1 via the intravenous and intramuscular routes, respectively; the protein had disappeared by day 42. Importantly, CCOL2A1 was not integrated into the host genome. CONCLUSIONS: These results indicate that pcDNA-CCOL2A1 vaccine is rapidly cleared within a short period of time and is therefore safe, and merits further development as a therapeutic vaccine for RA treatment.
has issue date	2019-09-06(xsd:dateTime)
bibo:doi	10.1186/s12951-019-0528-5
bibo:pmid	31492169
has license	cc-by
sha1sum (hex)	bc64088b806d6f43c4888ddb00a0479c8e57d33e
schema:url	https://doi.org/10.1186/s12951-019-0528-5
resource representing a document's title	Dynamic profiles, biodistribution and integration evaluation after intramuscular/intravenous delivery of a novel therapeutic DNA vaccine encoding chicken type II collagen for rheumatoid arthritis in vaccinated normal rodent
has PubMed Central identifier	PMC6729025
has PubMed identifier	31492169
schema:publication	J Nanobiotechnology
resource representing a document's body	covid:bc64088b806d6f43c4888ddb00a0479c8e57d33e#body_text
is schema:about of	named entity 'RHEUMATOID ARTHRITIS' named entity 'VACCINATED' named entity 'ENCODING' named entity 'integration' named entity 'host' named entity 'DNA vaccine' named entity 'profiles' named entity 'evaluation' named entity 'NORMAL' named entity 'DNA VACCINE' named entity 'NEW' named entity 'POTENTIAL' named entity 'BIODISTRIBUTION' named entity 'GENOME' named entity 'DNA VACCINE' named entity 'ITS' named entity 'PROFILE' named entity 'PRESENT' named entity 'PREVIOUSLY' named entity 'RODENT' named entity 'ENCODING' named entity 'VACCINATED' named entity 'INTRAVENOUS' named entity 'INTEGRATION' named entity 'DELIVERY' named entity 'DYNAMIC' named entity 'RISK OF' covid:arg/bc64088b806d6f43c4888ddb00a0479c8e57d33e named entity 'DNA INTEGRATION' named entity 'RODENT' named entity 'THERAPEUTIC' named entity 'BIODISTRIBUTION' named entity 'CHICKEN TYPE II COLLAGEN' named entity 'EVALUATION' named entity 'INTRAMUSCULAR' named entity 'NOVEL' named entity 'TREATMENT' named entity 'PERSISTENCE' named entity 'GENOMIC DNA' named entity 'RHEUMATOID ARTHRITIS' named entity 'CHARACTERIZED' named entity 'PRECLINICAL STUDIES' named entity 'CHICKEN TYPE II COLLAGEN' named entity 'INTEGRATION' named entity 'DYNAMIC' named entity 'BACKGROUND' named entity 'NORMAL' named entity 'THERAPEUTIC' named entity 'STUDY' named entity 'ESTABLISHED' named entity 'HOST' named entity 'biodistribution' named entity 'type II collagen' named entity 'study' named entity 'DNA' named entity 'rheumatoid arthritis' named entity 'vaccinated' named entity 'genome' named entity 'risk' named entity 'normal' named entity 'rodent' named entity 'biodistribution' named entity 'biodistribution' named entity 'DNA vaccine' named entity 'chicken' named entity 'biodistribution' named entity 'type II collagen' named entity 'intravenous' named entity 'rheumatoid arthritis' named entity 'protein' named entity 'blood samples' named entity 'RT-qPCR' named entity 'CFDA' named entity 'DNA vaccines' named entity 'cellular immune responses' named entity 'lung'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software